Zymergen, an Emeryville, Calif.-based molecular manufacturing technology company, raised over $400m in Series C funding.
The round was led by returning investor SoftBank Vision Fund, with participation from new investors Goldman Sachs and Hanwha Asset Management, as well as returning investors DCVC (Data Collective), True Ventures, Two Sigma Ventures, DFJ and Innovation Endeavors.
The company intends to use the funds to:
– double the capacity of its platform, increasing the speed and predictability with which it can program and optimize biology for specific traits, and
– begin commercializing products from its proprietary portfolio.
Led by Joshua Hoffman, co-founder and CEO, Zymergen is a molecular manufacturing technology company which leverages machine learning, automation, and bioengineering to improve the performance of materials and discover new molecular products that touch every industry – from manufacturing, to specialty chemicals, food and agriculture, electronics, and pharmaceuticals and more.
The technology is in use today, creating value for Fortune 1000 companies and major corporations across the globe.